{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:58:47Z","timestamp":1793044727619,"version":"4.5.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multiple basal cell carcinomas (BCCs) can result from a genetic disease, such as basal cell naevus syndrome (BCNS) or develop without a genetic predisposition, known as high-frequency BCC (HF-BCC). Multiple BCCs require frequent interventions, which may impact quality of life (QoL). Data on QoL in these patients and the influence of number of BCCs on QoL remain scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate QoL in patients with BCNS and HF-BCC and the impact of number of BCCs on QoL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with BCNS were recruited through the Maastricht University Medical Centre (MUMC+), the online national platform for patients with BCNS and through the Dutch Society for Dermatology and Venereology. Patients with HF-BCC (\u2265 9 BCCs in 3\u2005years or \u2265 6 in 10\u2005years) were recruited from the MUMC+ and Catharina Hospital Eindhoven. QoL was measured with the Skindex-29 and severity of QoL impact was calculated based on predefined cutoff scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy-five patients with BCNS and 59 with HF-BCC were included. Patients with BCNS were often younger (median 48 vs. 74\u2005years), 61% (n = 46\/75) were women vs. 34% (n = 20\/59) of patients with HF-BCC, and 48% (n = 36\/75) had &amp;gt; 100 BCCs vs. 2% (n = 1\/59) of patients with HF-BCC. A substantial proportion of patients with BCNS reported a severe impact on emotions and functioning [36% (n = 27\/75) and 23% (n = 17\/75), respectively] and mean (SD) scores of 32.2 (20.8) and 18.9 (19.6), respectively. Adjusting for age and sex, the overall Skindex-29 score was higher in the BCNS group, with a between-group difference of 10 (95% confidence interval 2.5\u201317.5). Among patients with BCNS, BCC burden was negatively associated with QoL, with significantly higher scores in patients with &amp;gt; 100 compared with &amp;lt; 30 BCCs [mean (SD) total score of 32.0 (19.6) vs. 15.8 (11.6)]. This trend was not observed in patients with HF-BCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings highlight increased QoL impairment in patients with BCNS compared with others with multiple BCCs, especially with respect to emotional and functional wellbeing. This can be partly explained by the high BCC burden in this patient group. Our findings suggest that a high BCC burden is an indicator of psychosocial burden and underscore that disease-related challenges in emotional and social domains should be considered during consultations to improve patient support.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljag212","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T11:50:34Z","timestamp":1779450634000},"page":"451-460","source":"Crossref","is-referenced-by-count":1,"title":["Health-related quality of life in patients with basal cell naevus syndrome and high-frequency basal cell carcinoma: a questionnaire study"],"prefix":"10.1093","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6994-809X","authenticated-orcid":false,"given":"Anna A L","family":"Massella Patsea","sequence":"first","affiliation":[{"name":"Department of Dermatology, Maastricht University Medical Centre+ , Maastricht ,","place":["the Netherlands"]},{"name":"GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Centre+ , Maastricht ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9236-0379","authenticated-orcid":false,"given":"Myrthe M G","family":"Moermans","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Maastricht University Medical Centre+ , Maastricht ,","place":["the Netherlands"]},{"name":"GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Centre+ , Maastricht ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2006-6467","authenticated-orcid":false,"given":"Babette J A","family":"Verkouteren","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Maastricht University Medical Centre+ , Maastricht ,","place":["the Netherlands"]},{"name":"GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Centre+ , Maastricht ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9669-7353","authenticated-orcid":false,"given":"Patty J","family":"Nelemans","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Maastricht University , Maastricht ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aim\u00e9e H M M","family":"Arits","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Catharina Hospital Eindhoven , Eindhoven ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8578-901X","authenticated-orcid":false,"given":"Marlies","family":"Wakkee","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Erasmus University Medical Center Cancer Institute , Rotterdam ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5119-6451","authenticated-orcid":false,"given":"Em\u0151ke","family":"R\u00e1cz","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Medical Center Groningen , Groningen ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5625-9762","authenticated-orcid":false,"given":"Marcel","family":"Bekkenk","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Amsterdam UMC , Amsterdam ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9065-3050","authenticated-orcid":false,"given":"Klara","family":"Mosterd","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Maastricht University Medical Centre+ , Maastricht ,","place":["the Netherlands"]},{"name":"GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Centre+ , Maastricht ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"2026081811171050600_ljag212-B1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2340\/00015555-1009","article-title":"Incidence, prevalence and future trends of primary basal cell carcinoma in the Netherlands","volume":"91","author":"Flohil","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"2026081811171050600_ljag212-B2","doi-asserted-by":"crossref","first-page":"100022","DOI":"10.1016\/j.ejcskn.2024.100022","article-title":"Quality of life issues faced by patients with keratinocyte cancer: A systematic review","volume":"2","author":"Kennedy","year":"2024","journal-title":"EJC Skin Cancer"},{"key":"2026081811171050600_ljag212-B3","doi-asserted-by":"crossref","first-page":"adv40112","DOI":"10.2340\/actadv.v104.40112","article-title":"The burden of multiple basal cell carcinomas: a population-wide study","volume":"104","author":"Kappelin","year":"2024","journal-title":"Acta Derm Venereol"},{"key":"2026081811171050600_ljag212-B4","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2340\/00015555-3123","article-title":"Skin cancer associated genodermatoses: a literature review","volume":"99","author":"Schierbeck","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"2026081811171050600_ljag212-B5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/jamadermatol.2013.5870","article-title":"Assessing health-related quality of life for advanced basal cell carcinoma and basal cell carcinoma nevus syndrome: development of the first disease-specific patient-reported outcome questionnaires","volume":"150","author":"Mathias","year":"2014","journal-title":"JAMA Dermatol"},{"key":"2026081811171050600_ljag212-B6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bjd.20700","article-title":"A guideline for the clinical management of basal cell naevus syndrome (Gorlin-Goltz syndrome)","volume":"186","author":"Verkouteren","year":"2022","journal-title":"Br J Dermatol"},{"key":"2026081811171050600_ljag212-B7","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/imj.13429","article-title":"Cohort study of Gorlin syndrome with emphasis on standardised phenotyping and quality of life assessment","volume":"47","author":"Huq","year":"2017","journal-title":"Intern Med J"},{"key":"2026081811171050600_ljag212-B8","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jaad.2020.07.088","article-title":"Prevalence and risk factors for high-frequency basal cell carcinoma in the United States","volume":"84","author":"Chiang","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2026081811171050600_ljag212-B9","doi-asserted-by":"crossref","first-page":"e646","DOI":"10.1111\/jdv.16512","article-title":"High-frequency basal cell carcinoma in Danish patients: prevalence and consistency","volume":"34","author":"Saldanha","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026081811171050600_ljag212-B10","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.3390\/jcm14134678","article-title":"High-frequency basal cell carcinoma: demographic, clinical, and histopathological features in a Belgian cohort","volume":"14","author":"Wunderlich","year":"2025","journal-title":"J Clin Med"},{"key":"2026081811171050600_ljag212-B11","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1365-4632.2010.04658.x","article-title":"Quality of life and depression assessment in nevoid basal cell carcinoma syndrome","volume":"50","author":"Shah","year":"2011","journal-title":"Int J Dermatol"},{"key":"2026081811171050600_ljag212-B12","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/ajmg.a.34128","article-title":"Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS)","volume":"155A","author":"Bree","year":"2011","journal-title":"Am J Med Genet A"},{"key":"2026081811171050600_ljag212-B13","doi-asserted-by":"crossref","first-page":"e122744","DOI":"10.1172\/jci.insight.122744","article-title":"Frequent basal cell cancer development is a clinical marker for inherited cancer susceptibility","volume":"3","author":"Cho","year":"2018","journal-title":"JCI Insight"},{"key":"2026081811171050600_ljag212-B14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.det.2011.11.003","article-title":"The Skindex instruments to measure the effects of skin disease on quality of life","volume":"30","author":"Chren","year":"2012","journal-title":"Dermatol Clin"},{"key":"2026081811171050600_ljag212-B15","author":"de Korte"},{"key":"2026081811171050600_ljag212-B16","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1365-2133.2009.09306.x","article-title":"Quality of life in patients with epidermolysis bullosa","volume":"161","author":"Tabolli","year":"2009","journal-title":"Br J Dermatol"},{"key":"2026081811171050600_ljag212-B17","doi-asserted-by":"crossref","first-page":"adv00439","DOI":"10.2340\/00015555-3736","article-title":"Sex differences in health-related quality of life in patients with keratinocyte carcinomas","volume":"101","author":"Sampogna","year":"2021","journal-title":"Acta Derm Venereol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljag212\/68378721\/ljag212.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/195\/3\/451\/68378721\/ljag212.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/195\/3\/451\/68378721\/ljag212.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:22:14Z","timestamp":1787066534000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/195\/3\/451\/8692102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":17,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,5,25]]},"published-print":{"date-parts":[[2026,8,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljag212","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,5,25]]}}}